Cargando…
Combination of EGFR Inhibitor Lapatinib and MET Inhibitor Foretinib Inhibits Migration of Triple Negative Breast Cancer Cell Lines
Triple-negative breast cancer (TNBC) is the most challenging subtype to treat due to the lack of estrogen receptor, progesterone receptor, and HER2 expression, which excludes the usage of directed targeted therapy against them. Promising therapeutic targets are the hepatocyte growth factor receptor...
Autores principales: | Simiczyjew, Aleksandra, Dratkiewicz, Ewelina, Van Troys, Marleen, Ampe, Christophe, Styczeń, Ilona, Nowak, Dorota |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6162814/ https://www.ncbi.nlm.nih.gov/pubmed/30227653 http://dx.doi.org/10.3390/cancers10090335 |
Ejemplares similares
-
Gefitinib or lapatinib with foretinib synergistically induce a cytotoxic effect in melanoma cell lines
por: Dratkiewicz, Ewelina, et al.
Publicado: (2018) -
Expression level of EGFR and MET receptors regulates invasiveness of melanoma cells
por: Pietraszek‐Gremplewicz, Katarzyna, et al.
Publicado: (2019) -
Characterization of Melanoma Cell Lines Resistant to Vemurafenib and Evaluation of Their Responsiveness to EGFR- and MET-Inhibitor Treatment
por: Dratkiewicz, Ewelina, et al.
Publicado: (2019) -
Combination of Selected MET and EGFR Inhibitors Decreases Melanoma Cells’ Invasive Abilities
por: Simiczyjew, Aleksandra, et al.
Publicado: (2019) -
Combination effect of lapatinib with foretinib in HER2 and MET co-activated experimental esophageal adenocarcinoma
por: Hassan, Md. Sazzad, et al.
Publicado: (2019)